Zoeken
Recidief PC, fase III, gehypofractioneerde versus standaard gefractioneerde RT
mCSPC, fase 3, HRRm en non-HRRm, AZD5305 (saruparib)
mHSPC, fase III, ADT +/- duralotamide
mCRPC, abiraterone versus enzalutamide
Neuro-endocrien prostaatcarcinoom, fase Ib/II, immuuntherapie
mCRPC, fase III, MK-5684 + HRT vs abiraterone / enzalutamide
mCRPC, moleculaire screening
Prostaatcarcinoom, fase 1, AZD5305 (saruparib) en darolutamide
Solide tumoren, HER2-mutatie/amplificatie, fase 1 populatie, zongertinib
HER2+ solide tumoren, fase 1, ELVN-002
mCRPC, fase 1, Lu-PSMA-617
Solide tumoren, EMA geregistreerde middelen
Solide tumoren, ‘actionable’ moleculaire target
Urologische tumoren
Formulier
